Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Wayne A. Ray
Bleeding in Patients With Atrial Fibrillation
Bleeding in Patients With Atrial Fibrillation Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban Wayne A. Ray, PhD; Cecilia P. Chung, MD, MPH; C. Michael Stein, MB, ChB; Walter Smalley, MD, MPH; Eli Zimmerman, MD; William D. Dupont, PhD; Adriana M. Hung, MD, MPH; James R. Daugherty, MS; Alyson Dickson, MA; Katherine T. Murray, MD Bleeding in Patients With Atrial Fibrillation—Reply Wayne A. Ray, PhD; C. Michael Stein, MB, ChB; Katherine T.
Bleeding in Patients With Atrial Fibrillation-Reply
Bleeding in Patients With Atrial Fibrillation—Reply Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban Wayne A. Ray, PhD; Cecilia P. Chung, MD, MPH; C. Michael Stein, MB, ChB; Walter Smalley, MD, MPH; Eli Zimmerman, MD; William D. Dupont, PhD; Adriana M. Hung, MD, MPH; James R. Daugherty, MS; Alyson Dickson, MA; Katherine T. Murray, MD Bleeding in Patients With Atrial Fibrillation Bethany T.
Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban
Key Points Question Do patients with atrial fibrillation receiving apixaban or rivaroxaban and concurrently treated for ventricular rate control with diltiazem have greater risk of serious bleeding than those treated with metoprolol? Findings In this cohort study of 204 155 patients aged 65 years or older, those treated with diltiazem had a significantly greater risk of serious bleeding compared with those treated with metoprolol.
Antipsychotic Medications and Mortality in Children and Young Adults
Key Points Question Is antipsychotic treatment of children and young adults without severe somatic illness or psychosis associated with increased risk of death? Findings In a cohort of 2 067 507 Medicaid patients aged 5 to 24 years, antipsychotic treatment was associated with increased risk of death only for patients with doses greater than 100-mg chlorpromazine equivalents. Risk was not significantly associated with lower doses or with either dose in children aged 5 to 17 years.
Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation-Reply
April 5, 2022 JAMA. 2022;327(13):1290. doi:10.1001/jama.2022.1428 Original Investigation Rivaroxaban vs Apixaban and Major Ischemic or Hemorrhagic Events in Patients With AF Wayne A. Ray, PhD; Cecilia P. Chung, MD, MPH; C. Michael Stein, MB, ChB; Walter Smalley, MD, MPH; Eli Zimmerman, MD; William D. Dupont, PhD; Adriana M. Hung, MD, MPH; James R. Daugherty, MS; Alyson Dickson, MA; Katherine T.
Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation
Key Points Question Is there a difference in risk of major ischemic or hemorrhagic events in patients with atrial fibrillation treated with rivaroxaban vs apixaban?
Apixaban may be safer for older patients with AF vs. rivaroxaban
December 21, 2021 3 min read Save Source/Disclosures Published by: Disclosures: Ray reports receiving grants from the NHLBI. Please see the study for all other authors’ relevant financial disclosures. Ferro and the other editorial authors report no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request.
Mortality and concurrent use of opioids and hypnotics in older patients: A retrospective cohort study
Loading metrics Open Access Peer-reviewed Research Article Wayne A. Ray , Cecilia P. Chung, Katherine T. Murray, Beth A. Malow, James R. Daugherty, C. Michael Stein Wayne A. Ray, Cecilia P. Chung, Katherine T. Murray, Beth A. Malow, James R. Daugherty, C.
A Closer Look at Hospitalizations for Gastrointestinal Bleeding
A study has found the incidence of hospitalizations for upper gastrointestinal tract bleeding is lower when patients receive co-therapy consisting of proton pump inhibitors and anticoagulants. Serious upper gastrointestinal (GI) tract bleeding is a frequent and potentially serious complication that has been linked to treatment with oral anticoagulants. “Proton pump inhibitors (PPIs), which promote healing of upper GI lesions, might reduce the risk of such bleeding,” explains Wayne A. Ray, PhD.
Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths
[Skip to Content Landing] Figure.
Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding
Key Points Question Are anticoagulant drug choice and proton pump inhibitor (PPI) cotherapy associated with the risk of upper gastrointestinal tract bleeding in Medicare beneficiaries? Findings During 754 389 person-years of anticoagulation treatment with apixaban, dabigatran, rivaroxaban, and warfarin, the risk of hospitalization for upper gastrointestinal tract bleeding was highest for rivaroxaban.
Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain
Importance Long-acting opioids increase the risk of unintentional overdose deaths but also may increase mortality from cardiorespiratory and other causes. Objective To compare all-cause mortality for patients with chronic noncancer pain who were prescribed either long-acting opioids or alternative medications for moderate to severe chronic pain.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Wayne A.
Contact Wayne A., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack